Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of the American College of Cardiology

• Publication date

  2004-04-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JACC.2003.11.045PMID 15093870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

  2004cited by this paper
• Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy.

  2003cited by this paper
• Metabolic Approaches to the Treatment of Ischemic Heart Disease: The Clinicians' Perspective

  2002cited by this paper
• Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.

  2001cited by this paper
• Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.

  2001cited by this paper
• Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.

  1999cited by this paper
• Antianginal Effects of Ranolazine in Various Experimental Models of Angina

  1999cited by this paper
• A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.

  1999cited by this paper
• Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group.

  1998cited by this paper
• Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group.

  1998cited by this paper
• Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate.

  1998cited by this paper
• Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial

  1998cited by this paper
• Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials.

  1997cited by this paper
• Statistical Considerations for Multiplicity in Confirmatory Protocols

  1996cited by this paper
• Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism.

  1996cited by this paper
• Protective Effects of Ranolazine on Ventricular Fibrillation Induced by Activation of the ATP-Dependent Potassium Channel in the Rabbit Heart

  1996cited by this paper
• Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.

  1996cited by this paper
• Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group.

  1995cited by this paper
• Antianginal efficacy and safety of controlled-delivery diltiazem QD versus an equivalent dose of immediate-release diltiazem TID

  1995cited by this paper
• Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart.

  1994cited by this paper
• Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias.

  1994cited by this paper
• Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris.

  1994cited by this paper
• Protective effects of ranolazine in guinea‐pig hearts during low‐flow ischaemia and their association with increases in active pyruvate dehydrogenase

  1993cited by this paper
• Application of computerized exercise ECG digitization. Interpretation in large clinical trials.

  1992cited by this paper
• A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators.

  1992cited by this paper
• Effects of a New Metabolic Modulator, Ranolazine, on Exercise Tolerance in Angina Pectoris Patients Treated with β‐Blocker or Diltiazem

  1992cited by this paper
• Indoor Air Pollution: A Health Perspective

  1992cited by this paper
• Multiple testing in clinical trials.

  1991cited by this paper
• Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group.

  1990cited by this paper
• Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion

  1990cited by this paper
• Exercise treadmill score for predicting prognosis in coronary artery disease.

  1987cited by this paper
• The effects of the novel anti-anginal agent RS 43285 on [lactic acid], [K+] and pH in a canine model of transient myocardial ischaemia

  1987cited by this paper
• Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction.

  1981cited by this paper
• Surgical management of acute and chronic cardiac mechanical complications due to myocardial infarction.

  1981cited by this paper
• Metabolic response of the heart in acute myocardial infarction in man.

  1978cited by this paper
• A double-blind trial of perhexiline maleate in the prophylaxis of angina pectoris.

  1976cited by this paper
• MALNUTRITION AND SCHOOL PROGRESS

  1975cited by this paper
• Initial metabolic and hormonal response to acute myocardial infarction.

  1974cited by this paper
• Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction.

  1968cited by this paper
• EMERGENCY HYPOTHERMIC IN MENINGOCOCCAL MENINGITIS.

  1965cited by this paper
• Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report.

  1962cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Effects of GS-967, GS-6615 and ranolazine on the responses of the rabbit aorta to adrenergic nerve stimulation

  2026cites this paper
• Unraveling the pharmacological and therapeutic potential of Ranolazine beyond antianginal drug use: a new insight

  2025cites this paper
• The History of Angina and Its Remedies: COURAGE, ORBITA, and a Path Forward.

  2025cites this paper
• Vagus nerve stimulation: A targeted approach for reducing tissue-specific ischemic reperfusion injury.

  2025cites this paper
• Antiischemic therapy in treating chronic coronary syndrome

  2025cites this paper
• Contemporary Antianginal Therapy

  2025influential citation
• Angina in stable coronary artery disease: Data from ORBITA and ORBITA-2.

  2025cites this paper
• Management of Symptomatic Patients with Chronic Coronary Syndromes: A Case-based Review on the Role of Ranolazine

  2025cites this paper
• Development trend analysis of ranolazine, based on bibliometrics

  2025cites this paper
• Ranolazine: An Established Anti-Anginal Drug with Emerging Antidiabetic Potential Supported by Preclinical and Clinical Evidence.

  2025cites this paper
• Are ORBITA trials practice-changing?

  2025cites this paper
• Energy metabolism in cardiovascular diseases: unlocking the hidden powerhouse of cardiac pathophysiology

  2025cites this paper
• Drug repurposing: A multi targetted approach to treat cardiac disease from existing classical drugs to modern drug discovery.

  2024cites this paper
• Ranolazine Unveiled: Rediscovering an Old Solution in a New Light

  2024cites this paper
• Ranolazine toxicity precipitating seizure in the elderly

  2024influential citation
• Current ideas about the role of ranolazine in patients’ treatment with angina pectoris

  2024cites this paper
• Ranolazine effects on exercise tolerance and angina frequency in Taiwanese stable angina: A bridging study of the CARISA randomized trial.

  2024cites this paper
• The Role of the CPT Family in Cancer: Searching for New Therapeutic Strategies

  2024cites this paper
• Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy

  2024cites this paper
• Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial

  2024cites this paper
• The Role of Ranolazine in the Treatment of Ventricular Tachycardia and Atrial Fibrillation: A Narrative Review of the Clinical Evidence

  2024cites this paper
• Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.

  2023cites this paper
• 2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome.

  2023cites this paper
• Changing the Orbit around Percutaneous Coronary Intervention for Stable Angina.

  2023cites this paper
• A QBD WITH THE FRACTIONAL FACTORIAL DESIGN WAS USED TO MATCH THE SIMILARITY BETWEEN RANOLAZINE EXTENDED-RELEASE TABLETS 500 MG AND 1000 MG

  2023cites this paper
• Structural basis for inhibition of the cardiac sodium channel by the atypical antiarrhythmic drug ranolazine

  2023cites this paper
• A Placebo-controlled Trial of Percutaneous Coronary Intervention for Stable Angina

  2023cites this paper
• Effect of Coronary Sinus Reducer Implantation on Aerobic Exercise Capacity in Refractory Angina Patients—A CROSSROAD Study

  2023cites this paper
• ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial

  2023cites this paper
• Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study

  2022influential citation
• Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis.

  2022cites this paper
• Role of ranolazine in heart failure: From cellular to clinic perspective.

  2022cites this paper
• Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center.

  2022cites this paper
• Exercise in Patients with Chronic Angina Pectoris: Friend or Foe?

  2022cites this paper
• Stable Ischemic Heart Disease and Approach to Chronic Chest Pain

  2022cites this paper
• Diagnostik, Therapie und die Bedeutung der Lebensqualität von Patienten mit chronischem Koronarsyndrom

  2022cites this paper
• The Effect Of Ranolazine Treatment Administered Before Coronary Artery Bypass Surgery On Perioperative Myocardial Damage In Patients With Stable Angina Pectoris

  2022cites this paper
• Stereoselective quantitative analysis of ranolazine in plasma and tissue samples: application in pharmacokinetics and tissue distribution studies

  2022cites this paper
• The sham effect of invasive interventions in chronic coronary syndromes: a systematic review and meta-analysis

  2022cites this paper
• Is it possible that angioplasty does not improve the quality of life in patients with stable angina?

  2022cites this paper
• Coronary Heart Disease and Myocardial Ischemia

  2021cites this paper
• Impact of ranolazine on exercise tolerance and arrhythmias in patients with INOCA

  2021cites this paper
• Diabetes mellitus aggravates ranolazine-induced ECG changes in rats

  2021cites this paper
• Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial): Rationale, Design, and Clinical Considerations.

  2021cites this paper
• State of the art approach to managing angina and ischemia: tailoring treatment to the evidence.

  2021cites this paper
• Evaluation of the Impact of Ranolazine Treatment on Liver Function Tests in Patients With Coronary Heart Disease and Nonalcoholic Fatty Liver Disease

  2021cites this paper
• Relief of Ischemia in Ischemic Cardiomyopathy

  2021cites this paper
• Ranolazine: a better understanding of pathophysiology and patient profile to guide treatment of chronic stable angina.

  2021cites this paper
• Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study

  2021cites this paper
• Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning

  2021cites this paper
• Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension

  2021cites this paper
• Dose-Dependent Effects of Ranolazine on Reentrant Ventricular Arrhythmias Induced After Subacute Myocardial Infarction in Rabbits

  2020cites this paper
• Treatment of stable ischaemic heart disease: the old and the new

  2020cites this paper
• Ranolazine alleviates contrast-associated acute kidney injury through modulation of calcium independent oxidative stress and apoptosis.

  2020cites this paper
• Diabetes and Metabolism

  2020cites this paper
• Refractory Angina-Unsolved Problem.

  2020cites this paper
• A novel method to interpret early phase trials shows how the narrowing of the coronary sinus concordantly improves symptoms, functional status and quality of life in refractory angina

  2020cites this paper
• Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction—A Systematic Review and Meta-analysis of Randomized Trials

  2020cites this paper
• CLINICAL COURSE OF A DEATH FROM RANOLAZINE OVERDOSE: A CASE REPORT

  2020cites this paper
• Ações Transmurais Inotrópicas e Antiarrítmicas da Ranolazina em um Modelo Celular da Síndrome do QT Longo Tipo 3

  2020cites this paper
• Chronic Stable Angina

  2020cites this paper
• Aberrant cardiac metabolism leads to cardiac arrhythmia.

  2020cites this paper
• Inotropic and Antiarrhythmic Transmural Actions of Ranolazine in a Cellular Model of Type 3 Long QT Syndrome

  2020cites this paper
• Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

  2020cites this paper
• Ranolazine in refractory and chronic stable angina

  2020cites this paper
• Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ.

  2020cites this paper
• Mitochondria in the Pulmonary Vasculature in Health and Disease: Oxygen-Sensing, Metabolism, and Dynamics.

  2020cites this paper
• Evidence in Guidelines for Treatment of Coronary Artery Disease.

  2020cites this paper
• Relaxant and antiadrenergic effects of ranolazine in human saphenous vein.

  2020cites this paper
• Lessons Learnt from Recent Trials in Ischemic Heart Disease

  2020cites this paper
• Late Sodium Current Inhibitors as Potential Antiarrhythmic Agents

  2020cites this paper
• Ranolazine Improves Right Ventricular Function in Patients With Precapillary Pulmonary Hypertension: Results From a Double-Blind, Randomized, Placebo-Controlled Trial.

  2020cites this paper
• The Possible Antidiabetic Effects of Ranolazine Versus Gliclazide In HFD/STZ-Induced Type 2 Diabetes In Male Albino Rats

  2020cites this paper
• Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris.

  2019cites this paper
• Herzinsuffizienz: "From Bench to Bedside"-Neues im Bereich der Ionenhomöostase

  2019cites this paper
• CORONARY ARTERY DISEASE TREATMENT

  2019cites this paper
• Role of Late Sodium Current During Repolarization and Its Pathophysiology

  2019cites this paper
• Contemporary Management of Patients with Stable Ischemic Heart Disease

  2019cites this paper
• Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial

  2019cites this paper
• Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease.

  2019cites this paper
• Advances in small-molecule therapy for managing angina pectoris in the elderly

  2019cites this paper
• Use of FDA’s Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure

  2019cites this paper
• Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction ancillary study.

  2019cites this paper
• Ranolazine Induced Bradycardia, Renal Failure, and Hyperkalemia: A BRASH Syndrome Variant

  2019cites this paper
• Late sodium current associated cardiac electrophysiological and mechanical dysfunction

  2018cites this paper
• ORBITA revisited: what it really means and what it does not?

  2018cites this paper
• Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension

  2018cites this paper
• Stable Angina Medical Therapy Management Guidelines: A Critical Review of Guidelines from the European Society of Cardiology and National Institute for Health and Care Excellence

  2018influential citation
• Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective

  2018cites this paper
• Efficacy and safety of ranolazine in the treatment of type 2 diabetes mellitus: a Meta-analysis

  2018influential citation
• ANY ROLE OF PCI IN STABLE CAD

  2018cites this paper
• Rethinking revascularization in patients with stable angina

  2018cites this paper
• ЭФФЕКТИВНОСТЬ ЧРЕСКОЖНОГО ВМЕШАТЕЛЬСТВА НА КОРОНАРНЫХ АРТЕРИЯХ У БОЛЬНЫХ СО СТАБИЛЬНОЙ СТЕНОКАРДИЕЙ: РЕЗУЛЬТАТЫ ДВОЙНОГО СЛЕПОГО РАНДОМИЗИРОВАННОГО КОНТРОЛИРУЕМОГО ИССЛЕДОВАНИЯ ORBITA (OBJECTIVE RANDOMISED BLINDED INVESTIGATION WITH OPTIMAL MEDICAL THERAPY OF ANGIOPLASTY IN STABLE ANGINA)

  2018influential citation
• Ranolazine (Ranexa®) June 2007

  2018cites this paper
• Cardiovascular drugs attenuated myocardial resistance against ischaemia-induced and reperfusion-induced injury in a rat model of repetitive occlusion

  2018cites this paper
• Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?

  2018cites this paper
• A Randomized Comparative Study on Efficacy and Safety Profile of Ivabradine and Ranolazine, in Patients of Chronic Stable Angina Pectoris

  2018influential citation
• The ORBITA trial and the future of percutaneous coronary intervention for stable angina.

  2018cites this paper
• Effect of ranolazine on glycaemia in adults with and without diabetes: a meta-analysis of randomised controlled trials

  2018cites this paper
• Impact of ranolazine on ventricular arrhythmias – A systematic review

  2018cites this paper